- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01696474
Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease (CAD0111)
October 26, 2017 updated by: Gruppo Italiano Malattie EMatologiche dell'Adulto
This multicenter, phase II, open label study will enroll patients with chronic cold agglutinin disorder.
A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Based on its activity in MM, single agent Bortezomib was tested in phase II trials in lymphoplasmacytic lymphoma, the disorder most frequently associated with CAD, and achieved 40-80% responses.
These striking clinical responses indicate that proteasome activity is critical for the survival of immunoglobulin-secreting cells.
The resolution of transfusion requirement in two patients with refractory CAD associated with IgMk monoclonal gammopathy has been reported after treatment with a short course of Bortezomib.
It may be interesting to test the efficacy of Bortezomib in a larger series of patients with refractory CAD, idiopathic or associated with an otherwise asymptomatic B cell clonal disorder, and to evaluate the duration of clinical benefit.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Foggia, Italy
- Struttura Complessa di Ematologia Ospedali Riuniti Foggia - Azienda Ospedaliero-Universitaria
-
Milano, Italy
- Centro Trapianti di Midollo - IRCCS Ospedale Maggiore Policlinico
-
Parma, Italy
- Cattedra di Ematologia CTMO Università degli Studi di Parma
-
Pescara, Italy
- U.O. Ematologia Clinica - Azienda USL di Pescara
-
Reggio Calabria, Italy, 89100
- Azienda Ospedaliera Bianchi Melacrino Morelli
-
Roma, Italy
- Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia
-
Udine, Italy
- Clinica Ematologica - Policlinico Universitario
-
Vicenza, Italy, 36100
- Ospedale San Bortolo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with chronic cold agglutinin disorder requiring or with a hemoglobin concentration below 10g/L determined at least monthly during the two months before entering the trial;
- Failure of at least one previous treatment attempt;
- Hemoglobin level assessment;
- Presence of serum cold agglutinin (CA). If an overnight incubation is used for CA detection, a titer at 4°C of 64 or higher is required;
- Written informed consent.
Exclusion Criteria:
- Presence of a concomitant lymphoproliferative disorder requiring specific treatment for reasons other than cold agglutinin related hemolytic anemia;
- Preexisting peripheral neuropathy;
- Known hypersensitivity to Bortezomib;
- Non-cooperative behaviour or non-compliance;
- Psychiatric diseases or conditions that might impair the ability to give informed consent;
- Patients who are pregnant (women of childbearing potential must have a negative serum pregnancy test). Post-menopausal women must be amenorrhoic for at least 24 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Bortezomib therapy
A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11.
Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients who become transfusion-free after Bortezomib therapy.
Time Frame: After 3 months from study entry.
|
Cumulative proportion of patients transfusion-free at three months after Bortezomib therapy.
|
After 3 months from study entry.
|
Number of patients who have never been transfused with a >2g hemoglobin rise compared to baseline.
Time Frame: After 3 months from study entry.
|
After 3 months from study entry.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of CTC grade 3 and 4 adverse events.
Time Frame: After 12 months from study entry.
|
Evaluation of the incidence of CTC grade 3 and 4 adverse events during and after treatment.
|
After 12 months from study entry.
|
Duration in months of transfusion independence.
Time Frame: At 12 months from study entry.
|
At 12 months from study entry.
|
|
Effect of treatment on the underlying clonal B cell disorder.
Time Frame: At 3 months from study entry.
|
At 3 months from study entry.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Giuseppe Rossi, Dr., S.C. Ematologia e Dipartimento di Oncologia Medica Spedali Civili - Brescia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2012
Primary Completion (ACTUAL)
March 27, 2017
Study Completion (ACTUAL)
March 27, 2017
Study Registration Dates
First Submitted
September 27, 2012
First Submitted That Met QC Criteria
September 27, 2012
First Posted (ESTIMATE)
October 1, 2012
Study Record Updates
Last Update Posted (ACTUAL)
October 27, 2017
Last Update Submitted That Met QC Criteria
October 26, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAD0111
- EudraCT number 2011-006329-42
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Cold Agglutinin Disease
-
SanofiRecruitingCold Agglutinin Disease (CAD) | Cold Agglutinin Syndrome (CAS)United States, Austria, France, Italy, Germany, Japan, Spain, United Kingdom
-
Bioverativ, a Sanofi companyCompletedAgglutinin Disease, ColdUnited States, Israel, Australia, Spain, Austria, Germany, Belgium, France, Canada, Italy, Japan, Norway, Netherlands, United Kingdom
-
Novartis PharmaceuticalsActive, not recruitingImmune Thrombocytopenia (ITP) | Cold Agglutinin Disease (CAD)United States, Spain, Germany, Korea, Republic of, United Kingdom, Italy
-
Swedish Orphan BiovitrumSuspendedCold Agglutinin DiseaseSpain, Belgium, Norway, United States, Japan, United Kingdom, Netherlands, Canada, Hungary, Austria, Finland, Georgia, Germany, Italy
-
SanofiCompleted
-
Bioverativ, a Sanofi companyCompletedCold Agglutinin DiseaseUnited States, United Kingdom, Israel, Australia, Spain, Austria, Germany, France, Belgium, Japan, Canada, Netherlands, Italy, Norway
-
University Hospital, EssenAlexion PharmaceuticalsCompleted
-
University of BergenCompleted
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNot yet recruitingLymphomaNorway, Netherlands, Denmark, Belgium
-
Bioverativ, a Sanofi companyAssign Data Management and Biostatistics GmbH; Quest Diagnostics-Nichols Insitute and other collaboratorsCompletedEnd-stage Renal Disease (ESRD) | Cold Agglutinin Disease (CAD) | Bullous Pemphigoid (BP) | Warm Autoimmune Hemolytic Anemia (WAIHA)Austria
Clinical Trials on Bortezomib
-
The First Affiliated Hospital of Soochow UniversityUnknownMultiple Myeloma Proved by Laboratory TestsChina
-
Baylor College of MedicineMillennium Pharmaceuticals, Inc.CompletedProstate NeoplasmsUnited States
-
NCIC Clinical Trials GroupCompleted
-
University Hospital, Clermont-FerrandLaboratoires TakedaUnknownMultiple Myeloma | Adult | Bortezomib RegimenFrance
-
Janssen-Cilag International NVCompletedMultiple MyelomaTurkey, Greece, Czech Republic, Austria, Germany, Sweden, United Kingdom, Denmark
-
University Health Network, TorontoNational Cancer Institute (NCI)CompletedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and UreterUnited States, Canada
-
Southwest Oncology GroupNational Cancer Institute (NCI)Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
NYU Langone HealthNational Cancer Institute (NCI)CompletedLymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol SpecificUnited States